相关实验视频

Updated: Sep 18, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

使用患者衍生的细胞系进行的药理定律分析预测了皮肤纤维瘤原生菌瘤患者对伊马替尼的敏感性

Rei Noguchi1, Takuya Ono1, Kazuki Sasaki2,3

  • 1Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Cells
|June 25, 2025
PubMed
概括

确定了皮肤纤维素瘤突起体 (DFSP) 中伊马蒂尼布反应的预测生物标志物. 在患者衍生细胞系中酶活性概况显示FER,ITK和VEGFR1作为意马提尼布敏感性的潜在标志物.

关键词:
生物标志物生物标志物皮肤纤维细胞瘤 突起性 肌肉纤维细胞瘤药物查对药物进行查.伊马替尼布 (Imatinib) 的使用情况激酶活性激酶的活动.患者衍生细胞系患者衍生细胞系药物管理学 药物管理学肉瘤 肉瘤是一种肉瘤.

更多相关视频

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.6K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K